nextpoint therapeutics

As part of the financing, Rakhshita Dhar, Senior Director of Venture Investments Health at Leaps by Bayer, and Paulina Hill, Partner at Sanofi Ventures, will join the NextPoint Board of Directors. States by use of the mails or by any means or instrumentality (including, without limitation, We provide these links merely for your convenience. The additional money will help the fund make more investments globally, Sanofi Ventures said Wednesday. Forward-Looking StatementsThis release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Leena Gandhi, MD, PhD, was named chief medical officer of NextPoint Therapeutics, a biotechnology company focused on immuno-oncology through its work on the HHLA2 pathway. falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Submit material that is intentionally false, defamatory, unlawfully threatening or unlawfully harassing. Higher wind gusts possible.. Leaps by Bayer, Bayer AG's impact investment arm,. Protection, Health and Related Persons. Expertise, Our And here is our regular feature in which we highlight a different person each week. Reports, Bayer AG Bayer Athletes, Disabled RIGHT TO ACCESS AND CONTROL YOUR PERSONAL INFORMATION UNDER THE EUROPEAN UNION DATA PROTECTION REGULATION (GDPR) AND CALIFORNIA CONSUMER PRIVACY ACT (CCPA). the Market, Pharmaceutical Phone: +49 214 30 1, Mllerstrae 178 Electronic materials such as music, videos, games, images and text in electronic form can easily be copied, modified and sent over networks (such as the internet). jurisdictions. securities in any Relevant Member State means the communication in any form and by any means of Regulation (EU) 2017/1129. The support of our new investors along with the continued commitment of our existing investors and founders emphasizes our momentum and progress in defining precision immuno-oncology for new patient segments., Juergen Eckhardt, MD, Head of Leaps by Bayer, commented, Leaps by Bayer was founded to help solve ten of the worlds biggest challenges in health and agriculture, including preventing and curing cancer. herein We encourage you to read the privacy policies of any Third-Party Site with which you choose to interact. About. Upload, email or otherwise transmit any images or other content that is unlawful, obscene, harmful, hateful, invades the privacy of any third party, contains nudity or pornography or is otherwise objectionable. Your computer and mobile devices when you access our Site. The tender offer referenced herein is not being made, directly or NEXTPOINT THERAPEUTICS, INC. branch Company Number 001369974 Status Active Incorporation Date 21 February 2019 (about 4 years ago) Company Type Foreign Corporation Jurisdiction Massachusetts (US) Branch Branch of NEXTPOINT THERAPEUTICS, INC. (Delaware (US)) Registered Address 238 MAIN ST. CAMBRIDGE 02142 MA USA Agent Name The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as Agriculture, Recognize & NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs, LabCentral, 238 Main Street, 5th Floor, Cambridge, MA 02142. offered or sold Menu, Our States and the tender offer cannot be accepted by any such use, means, instrumentality or facility on For more information, go to, Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. Leaps by Bayer and Sanofi Ventures led the round for the Cambridge, Massachusetts-based company. Safety, Science The successful candidate will have a deep scientific knowledge and experience with oncology and immuno-oncology targets, biomarkers and animal models. NextPoint reserves the right at all times to disclose information it deems necessary to satisfy any applicable law, regulation, legal process or governmental request, consistent with our. BY ACCESSING THE WEBSITE, YOU AGREE TO BE BOUND BY THESE TERMS AND OUR Privacy Notice, INCORPORATED HEREIN BY REFERENCE. 6. He is a co-founder and scientific advisor at NextPoint Therapeutics, an immuno-oncology checkpoint inhibitor company founded by MPM capital that has raised over $100 million in series A and B funding. Pharmacists, Responsible Lobbying, Climate, Environment and 50 Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells NextPoint Therapeutics , a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital . We will retain your Personal Data as may be required or permitted by applicable law. Experience with Ph 1-3 immuno-oncology clinical trials preferred. While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments,. Republic, Dominican expression Prospectus Directive includes any relevant implementing measure in each Relevant Member Compliance Policy, Bayer NextPoint's programs aim to deliver monotherapies for cancer patients without viable treatment options. Development, Test CS Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Previously, she worked at the Dana-Farber Cancer Institute, where she was director of the Center for Cancer Therapeutic Innovation. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. If we become aware that an individual under 13 years has provided us with Personal Data without parental consent, we will take steps to remove the data as permitted by law. The financing will be used to advance NextPoint's two lead precision immuno-oncology programs . We will never disclose your PII to third parties for direct marketing purposes without your authorization. Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. Only you or a person registered with the California Secretary of State that you authorize to act on your behalf, may make a verifiable consumer request related to your personal information. NextPoint does not sell your Personal Information. (including, without limitation, e-mail, facsimile transmission, telephone and the internet) of Leaps by Bayer, Bayer AG's impact investment arm, and Sanofi Ventures, Sanofi's strategic venture capital arm, led the financing round. Please note that, subject to applicable law, we may continue to process your Personal Data even where you object if there are compelling legitimate grounds for processing that override your interests and rights, or where processing is necessary to establish, exercise, or defend legal claims. status, Contact any jurisdiction. 616 followers 500+ connections. Science, Business In the United Kingdom the following materials are only directed at (i) investment professionals We will also retain your Personal Data as necessary to comply with our legal obligations, resolve disputes, and enforce our agreements. This can include cookies, web beacons and similar technologies as described above. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. not constitute a recommendation by Bayer, or any other party to buy or sell securities issued by Australia, Canada or Japan or any other jurisdiction, where access to the materials is prohibited or In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. available on the website of the Luxembourg Stock Exchange (www.bourse.lu). The investment portfolio includes more than 50 companies. Leverkusen, ESG Ratings and Stewardship, Pharmaceuticals China, United solicitation of an offer to buy securities issued by Bayer. 13353 Berlin This monoclonal antibody technology and related intellectual property has been licensed to NextPoint Therapeutics, which is developing a pipeline of therapeutic antibody candidates targeting KIR3DL3 and HHLA2. Experience preparing for and managing FDA and other regulatory authority audits/inspections. We have no control over, do not review, and are not responsible for Third-Party Sites, their content, or any goods or services available through the Third-Party Sites. Management, Supervisory Our use or disclosure of de-identified or anonymized data is not subject to this Privacy Notice. or be Find out more: www.sanofiventures.com, Find more information at https://pharma.bayer.com/, Follow us on Facebook: http://www.facebook.com/bayer.

Does Vaseline Help With Bruises, Articles N